CITIGROUP PIPER JAFFRAYUnderwriting Agreement • May 10th, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 10.17 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. LICENSE AGREEMENT This Licensing Agreement (the "Agreement") is made effective the 1st day of March, 2002 (the...License Agreement • February 27th, 2004 • Alnylam Pharmaceuticals Inc • District of Columbia
ALNYLAM PHARMACEUTICALS, INC. 5,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • January 15th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Alnylam Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule I hereto (the “Underwriters”), for whom Barclays Capital Inc. is acting as representative (the “Representative”), an aggregate of 5,000,000 shares of common stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 750,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. To the extent there are no additional Underwriters listed in Schedule I hereto, all references herein to the Underwriters shall refer just to you.
EXHIBIT 1.1 4,700,000 SHARES ALNYLAM PHARMACEUTICALS, INC. Common Stock, Par Value $0.01 Per Share UNDERWRITING AGREEMENT December 12, 2006Underwriting Agreement • December 13th, 2006 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
EXHIBIT 10.5Registration Rights Agreement • February 27th, 2004 • Alnylam Pharmaceuticals Inc • Massachusetts
Exhibit 10.2 ALNYLAM PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2004 Stock Incentive Plan AGREEMENT made this 12th day of July, 2005, between Alnylam Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and James L....Restricted Stock Agreement • July 13th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
LEASELease • February 27th, 2004 • Alnylam Pharmaceuticals Inc • Massachusetts
EXHIBIT 10.11 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (THIS "AGREEMENT") dated as of December 18, 2002, between SILICON VALLEY BANK, a California chartered bank, with its principal place of business at 3003 Tasman Drive, Santa...Loan and Security Agreement • February 27th, 2004 • Alnylam Pharmaceuticals Inc • Delaware
ANDStock Purchase Agreement • September 12th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
ALNYLAM PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of September 15, 2022 1.00% Convertible Senior Notes due 2027Indenture • October 27th, 2022 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
INDENTURE dated as of September 15, 2022 between ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
Exhibit 10.13 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION...Warrant Agreement • February 27th, 2004 • Alnylam Pharmaceuticals Inc • Massachusetts
Exhibit 10.1 ALNYLAM PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2004 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Alnylam Pharmaceuticals, Inc., a Delaware corporation (the "Company"), on...Nonstatutory Stock Option Agreement • July 13th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
AGREEMENTLicense Agreement • May 21st, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • California
ANDCollaboration Agreement • May 16th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
RECITALSLoan and Security Agreement • April 6th, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • California
DATE: September [ ], 2022 TO: Alnylam Pharmaceuticals, Inc. 675 West Kendall Street, Henri A. Termeer Square Cambridge, Massachusetts 02142 FROM: [Insert Dealer Name] SUBJECT: [Base][Additional] Call Option TransactionCall Option Transaction • September 16th, 2022 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer] (“Dealer”) and Alnylam Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
EXHIBIT 10.3 ALNYLAM PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2004 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Alnylam Pharmaceuticals, Inc., a Delaware corporation (the "Company"), on...Incentive Stock Option Agreement • August 11th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
ANDCollaboration and License Agreement • November 9th, 2006 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
FORM OF DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • August 4th, 2016 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
EXHIBIT 10.23 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. SPONSORED RESEARCH AGREEMENT Effective as of 1 OCTOBER 2003, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH,...Sponsored Research Agreement • May 21st, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • Mayo
EXHIBIT 10.18 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. LICENSE AGREEMENT This License Agreement (this "Agreement"), is effective December 30, 2003 (the "Effective...License Agreement • May 21st, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • New York
ALNYLAM PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of _______________ SUBORDINATED DEBT SECURITIESIndenture • July 21st, 2011 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
WHEREAS, the Issuer may from time to time duly authorize the issue of its unsecured subordinated debentures, notes or other evidences of indebtedness to be issued in one or more series (the “Securities”) up to such principal amount or amounts as may from time to time be authorized in accordance with the terms of this Indenture;
LEASE by and between BMR-675 WEST KENDALL STREET LLC, a Delaware limited liability company and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporationLease • August 7th, 2015 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
IN WITNESS WHEREOF, Tenant has executed this Acknowledgment of Term Commencement Date and Term Expiration Date as of the date first written above.
EXHIBIT 10.2 VIA HAND DELIVERY October 9, 2006 Vincent J. Miles, Ph.D. 62 Woodchester Drive Chestnut Hill, MA 02467 Dear Vin: This letter agreement sets forth the terms of your continued employment with Alnylam Pharmaceuticals, Inc. (the "Company")....Employment Agreement • November 9th, 2006 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
EXHIBIT 10.12 UNCONDITIONAL GUARANTY For and in consideration of certain loans by SILICON VALLEY BANK, a California-chartered bank, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production...Unconditional Guaranty • February 27th, 2004 • Alnylam Pharmaceuticals Inc
BY AND BETWEENResearch Collaboration and License Agreement • March 2nd, 2009 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
ALNYLAM PHARMACEUTICALS, INC LICENCE AGREEMENTLicence Agreement • May 21st, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • London
Exhibit 10.12 NEITHER THIS WARRANT NOR THE PREFERRED STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"), OR ANY APPLICABLE STATE SECURITIES LAWS, AND NEITHER THIS WARRANT NOR...Preferred Stock Purchase Warrant • April 6th, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
EXECUTION INVESTOR RIGHTS AGREEMENT THIS INVESTOR RIGHTS AGREEMENT (the "AGREEMENT") is entered into as of September 8, 2003 by and between Alnylam Holding Co., a Delaware corporation (the "CORPORATION"), and Merck & Co., Inc., a New Jersey...Investor Rights Agreement • February 27th, 2004 • Alnylam Pharmaceuticals Inc • Delaware
LEASE RREEF AMERICA REIT II CORP. PPP, Landlord, and ALNYLAM PHARMACEUTICALS, INC., Tenant Riverfront Office Park Cambridge, MassachusettsLease • August 7th, 2015 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
By this Lease Landlord leases to Tenant and Tenant leases from Landlord the Premises in the Building as set forth and described on the Reference Pages. The Premises are depicted on the floor plan attached hereto as Exhibit A, and the Building is depicted on the site plan attached hereto as Exhibit A-1. The Building is located on the Lot legally described on Exhibit A-2. The Reference Pages, including all terms defined thereon, are incorporated as part of this Lease.
CREDIT AGREEMENT Dated as of April 29, 2016 Among ALNYLAM U.S., INC., as the Borrower, ALNYLAM PHARMACEUTICALS, INC., as Parent and Parent Guarantor, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as the LenderCredit Agreement • August 4th, 2016 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This CREDIT AGREEMENT is entered into as of April 29, 2016, among ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (the “Parent” or the “Parent Guarantor”), ALNYLAM U.S., INC., a Delaware corporation and a wholly-owned Subsidiary of Parent (the “Borrower” and, together with the Parent Guarantor, collectively the “Loan Parties” and, each individually, a “Loan Party”), and WELLS FARGO BANK, NATIONAL ASSOCIATION, as the Lender.
BETWEENRights Agreement • July 14th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
SETTLEMENT AGREEMENT AND GENERAL RELEASESettlement Agreement • February 19th, 2013 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Settlement Agreement and General Release (the “Agreement”) is entered into this 12th day of November 2012 (the “Effective Date”) by and among Tekmira Pharmaceuticals Corporation, a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8 (“TPC”), Protiva Biotherapeutics Inc., a wholly-owned subsidiary of TPC and a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8 (“Protiva”), Alnylam Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 300 Third Street, Cambridge, MA 02142 (“Alnylam”), and AlCana Technologies, Inc., a British Columbia corporation with a principal place of business at 2714 West 31st Avenue, Vancouver, British Columbia, Canada V6L 2A1 (“AlCana”). Each of TPC, Protiva, Alnylam, and AlCana shall be considered a “Party,” and collectively they shall be considered the “Parties.”
INVESTOR AGREEMENT By and BetweenInvestor Agreement • August 6th, 2019 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INVESTOR AGREEMENT (this “Agreement”) is made as of April 8, 2019, by and between Regeneron Pharmaceuticals, Inc. (the “Investor”), a New York corporation with its principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591, and Alnylam Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142.
ANDInvestor Rights Agreement • September 12th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
